Apatinib as an alternative therapy for advanced hepatocellular carcinoma

被引：0

作者：

Xi-Hao Zhang ^{[1
,2
]}

Man-Qing Cao ^{[2
,3
]}

Xiu-Xiu Li ^{[1
,2
,4
]}

Ti Zhang ^{[1
,2
,5
]}

机构：

[1] Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer

[2] Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University

[3] Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer

[4] Digestive Department, Shanxi Province Tumor Hospital

[5] Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital

来源：

World Journal of Hepatology | 2020年 / 12卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma(HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.

引用

页码：766 / 774

页数：9

共 50 条

[21] Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
Sun, Tao
Ren, Yanqiao
Kan, Xuefeng
Chen, Lei
Zhang, Weihua
Yang, Fan
Zheng, Chuansheng
FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
[22] A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
Huang, Julu
Liang, Rong
Lu, Cheng
Lu, Lu
Li, Shuanghang
Tang, Minchao
Huang, Xi
Huang, Shilin
Mai, Rongyun
Gao, Xing
Li, Shizhuo
Zeng, Can
Lin, Yan
Ye, Jiazhou
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
[23] Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Kan, Xuefeng
Liang, Bin
Zhou, Guofeng
Xiong, Bin
Pan, Feng
Ren, Yanqiao
Cao, Yanyan
Wang, Jihua
Yang, Fan
Zheng, Chuansheng
FRONTIERS IN ONCOLOGY, 2020, 10
[24] Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study
Yu, Wen-Chang
Zhang, Kong-Zhi
Chen, Shi-Guang
Liu, Wei-Fu
MEDICINE, 2018, 97 (03)
[25] Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
Zheng, Zhuangzhuang
Liu, Zijing
Zhang, Haifeng
Guo, Xiao
Jia, Xiaojing
Wang, Jianfeng
Meng, Lingbin
Xin, Ying
Jiang, Xin
FRONTIERS IN PHARMACOLOGY, 2022, 13
[26] Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study
Li, Tao
Zhao, Jingfang
Zhang, Shuai
Wang, Hui
Sun, Linlin
Hu, Jinhua
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (01) : 57 - 63
[27] Frontline therapy for advanced hepatocellular carcinoma: an update
Akce, Mehmet
El-Rayes, Bassel F.
Bekaii-Saab, Tanios S.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[28] Apatinib radiosensitizes hepatocellular carcinoma in vitro and in vivo
Huilin Jin
Junbin Liao
Lixia Xu
Qi Zhou
Sui Peng
Ming Kuang
Cancer Biology & Medicine, 2018, 15(S1) (S1) : 20 - 20
[29] Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma
Chen, Hu
Teng, Minglei
Zhang, Hongrui
Liang, Xiaoliu
Cheng, Hongwei
Liu, Gang
CHINESE CHEMICAL LETTERS, 2022, 33 (07) : 3371 - 3383
[30] Interventional and synthetic therapy of advanced hepatocellular carcinoma
Cao, XC
He, NS
Sun, JZ
Wang, S
Ji, XM
Fan, HL
Wang, JS
Zhang, CL
Yang, JG
Lu, TW
Li, JH
Zhang, GX
CHINESE MEDICAL JOURNAL, 2002, 115 (12) : 1883 - 1885

← 1 2 3 4 5 →